|Bid||142.93 x 800|
|Ask||143.02 x 800|
|Day's Range||142.61 - 144.09|
|52 Week Range||91.21 - 146.26|
|Beta (5Y Monthly)||0.79|
|PE Ratio (TTM)||45.92|
|Forward Dividend & Yield||0.80 (0.55%)|
|Ex-Dividend Date||Apr 15, 2020|
|1y Target Est||N/A|
Zoetis acquires Ethos Diagnostic Science, a veterinary reference lab business, to further expand its comprehensive diagnostics capabilities.
Simparica Trio™, a Once-Monthly Triple Combination Antiparasitic Medication for Dogs, receives Notice of Compliance from Health Canada's Veterinary Drugs Directorate
Zoetis Inc. will host a webcast and conference call at 8:30 a.m. on Tuesday, Aug. 6, 2019. Chief Executive Officer Juan Ramón Alaix and Executive Vice President and Chief Financial Officer Glenn David will review second quarter 2019 financial results and respond to questions from financial analysts during the call.
Zoetis Inc. (ZTS) will participate in the William Blair 39th Annual Growth Stock Conference on Thursday, June 6, 2019, in Chicago, Ill. Juan Ramón Alaix, Chief Executive Officer, will represent the company and respond to questions from analysts. Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 65 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines, medicines and diagnostics, which are complemented by genetic tests, biodevices and a range of services.